The abstract is read at the publisher; the summary is JClub's.
Updated ASCO living guideline evidence for epithelial ovarian cancer links PARPi use to progression-free survival benefits in frontline trials, while later-line and recurrent maintenance trials report potential overall survival disadvantages.
- Why it matters: Clinicians need clear, evidence-based guidance on when to use PARPi and which patients should receive HRD and genetic testing, balancing efficacy against safety and possible survival tradeoffs.
- What they did: An Expert Panel synthesized 79 publications, including 18 studies of 13 HRD assays and 31 pivotal PARPi trials, and translated randomized and cohort evidence into recommendations for testing and maintenance strategies.
- The result: The guideline recommends genetic testing for all newly diagnosed advanced EOC, prioritizing PARPi maintenance in first remission, restricting recurrent maintenance mainly to PARPi-naïve patients with BRCA 1/2 mutations, and avoiding PARPi monotherapy or combinations outside clinical trials.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.